Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial.

During the 24-week observation period in this study, the response rate showed a decreasing trend over time (from 78% [49 of 63] at week 8 to 60% [38 of 63] at week 24), and immunoglobulin levels remained below baseline levels, indicating the need for a longer follow-up period to further evaluate the long-term efficacy and safety of daratumumab treatment for immune thrombocytopenia.

also in 47,180 other papers